Annual EBITDA:
-$192.36M-$107.70M(-127.22%)Summary
- As of today, MLYS annual EBITDA is -$192.36 million, with the most recent change of -$107.70 million (-127.22%) on December 31, 2024.
- During the last 3 years, MLYS annual EBITDA has fallen by -$172.98 million (-892.52%).
- MLYS annual EBITDA is now -5709.73% below its all-time high of -$3.31 million, reached on December 1, 2020.
Performance
MLYS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$41.12M+$5.61M(+12.01%)Summary
- As of today, MLYS quarterly EBITDA is -$41.12 million, with the most recent change of +$5.61 million (+12.01%) on September 30, 2025.
- Over the past year, MLYS quarterly EBITDA has increased by +$18.98 million (+31.58%).
- MLYS quarterly EBITDA is now -534.60% below its all-time high of -$6.48 million, reached on June 1, 2022.
Performance
MLYS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$184.03M+$18.98M(+9.35%)Summary
- As of today, MLYS TTM EBITDA is -$184.03 million, with the most recent change of +$18.98 million (+9.35%) on September 30, 2025.
- Over the past year, MLYS TTM EBITDA has dropped by -$15.71 million (-9.33%).
- MLYS TTM EBITDA is now -2498.19% below its all-time high of -$7.08 million, reached on December 1, 2021.
Performance
MLYS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MLYS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -127.2% | +31.6% | -9.3% |
| 3Y3 Years | -892.5% | -453.9% | -777.0% |
| 5Y5 Years | -5709.7% | -480.5% | -2498.2% |
MLYS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -892.5% | at low | -453.9% | +31.6% | -777.0% | +9.3% |
| 5Y | 5-Year | -5709.7% | at low | -534.6% | +31.6% | -2498.2% | +9.3% |
| All-Time | All-Time | -5709.7% | at low | -534.6% | +31.6% | -2498.2% | +9.3% |
MLYS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$41.12M(+12.0%) | -$184.03M(+9.3%) |
| Jun 2025 | - | -$46.73M(-5.2%) | -$203.01M(-0.8%) |
| Mar 2025 | - | -$44.43M(+14.1%) | -$201.44M(-4.7%) |
| Dec 2024 | -$192.36M(-127.2%) | -$51.75M(+13.9%) | -$192.36M(-14.3%) |
| Sep 2024 | - | -$60.09M(-33.1%) | -$168.32M(-25.1%) |
| Jun 2024 | - | -$45.16M(-27.7%) | -$134.50M(-28.0%) |
| Mar 2024 | - | -$35.35M(-27.6%) | -$105.07M(-24.1%) |
| Dec 2023 | -$84.66M | -$27.71M(-5.5%) | -$84.66M(-26.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$26.27M(-67.0%) | -$66.95M(-39.2%) |
| Jun 2023 | - | -$15.73M(-5.3%) | -$48.10M(-23.8%) |
| Mar 2023 | - | -$14.94M(-49.3%) | -$38.85M(-62.5%) |
| Dec 2022 | -$31.48M(-62.4%) | -$10.01M(-34.8%) | -$23.91M(-13.9%) |
| Sep 2022 | - | -$7.42M(-14.6%) | -$20.98M(-54.7%) |
| Jun 2022 | - | -$6.48M(+8.5%) | -$13.56M(-91.5%) |
| Dec 2021 | -$19.38M(-485.4%) | - | - |
| Dec 2021 | - | -$7.08M | -$7.08M |
| Dec 2020 | -$3.31M | - | - |
FAQ
- What is Mineralys Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Mineralys Therapeutics, Inc.?
- What is Mineralys Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Mineralys Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Mineralys Therapeutics, Inc.?
- What is Mineralys Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Mineralys Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Mineralys Therapeutics, Inc.?
- What is Mineralys Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Mineralys Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of MLYS is -$192.36M
What is the all-time high annual EBITDA for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. all-time high annual EBITDA is -$3.31M
What is Mineralys Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, MLYS annual EBITDA has changed by -$107.70M (-127.22%)
What is Mineralys Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of MLYS is -$41.12M
What is the all-time high quarterly EBITDA for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. all-time high quarterly EBITDA is -$6.48M
What is Mineralys Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, MLYS quarterly EBITDA has changed by +$18.98M (+31.58%)
What is Mineralys Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of MLYS is -$184.03M
What is the all-time high TTM EBITDA for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. all-time high TTM EBITDA is -$7.08M
What is Mineralys Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, MLYS TTM EBITDA has changed by -$15.71M (-9.33%)